1 / 1

For further information please contact: Joy K Rahman

PET-NECK: A multi-centre randomised phase III trial comparing a PET-CT guided watch & wait policy versus planned neck dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head & neck squamous cancer. Objectives.

marja
Télécharger la présentation

For further information please contact: Joy K Rahman

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. PET-NECK: A multi-centre randomised phase III trial comparing a PET-CT guided watch & wait policy versus planned neck dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head & neck squamous cancer Objectives • PET NECK: Current treatment for patients with locally advanced head and neck squamous cell carcinoma is neck dissection before or after chemo-radiotherapy. This often results in high morbidity and mortality and alternative and better management is needed. PET-NECK is a phase III randomised controlled trial (560 patients) which is comparing PET-CT guided watch and wait policy versus planned neck dissection for the management of locally advanced head and neck cancer, in terms of: • Efficacy (overall survival, disease-specific survival, local control) • Cost-effectiveness (Health Resource use and Quality of Life) • Safety (complications) • For further information please contact: • Joy K Rahman • Clinical Trials Co-ordinator Warwick Clinical Trials Unit • Division of Health Sciences • Warwick Medical School • The University of Warwick • Coventry • CV4 7AL : +44 (0)2476 150 478 : +44 (0)2476 150 586 : J.K.Rahman@warwick.ac.uk www.warwick.ac.uk/wms Chief Investigator: Professor Hisham Mehanna University Hospitals Coventry & Warwickshire • Accrual duration: 5 years. • Target: 560 patients. • First patient randomised: October 2007. • Patients recruited: 479 as of 21/03/2012. • Planned close: September 2012. • Sites open to recruitment: 53. • Sites in set up: 4. • New sites: No longer open to new sites. • Local Sites Open: UHCW, Heartlands, New Cross Wolverhampton, Manor Hospital Walsall, QE Birmingham, Russells Hall. Schema HEAD & NECK SCC CANCER DIAGNOSIS • KEY ELIGIBILITY CRITERIA • Histological diagnosis of oropharyngeal, laryngeal, oral, hypopharyngeal or occult HN SCC • Clinical and CT/MRI evidence of N2 or N3 nodal metastases • MDT decision for curative concurrent CRT to primary and neck • Written consent and aged over 18 SURVEILLANCE ARM (280 Pts) Standard concomitant CRT. NECK DISSECTION ARM (280 Pts) Standard concomitant CRT with neck dissection (i.e. ND within 4 weeks of randomisation or 4 - 8 weeks after completion of CRT). PET-CT & assessment 13 weeks after CRT completion. (Neck dissection only if neck nodes are positive/equivocal). CT & assessment after completion of CRT. Portfolio Trial Number: 6082

More Related